EPCT-09. ROVER: A phase 1/2 study of avapritinib in pediatric patients with solid tumors dependent on KIT or PDGFRA signaling von Chi, Susan, Hsieh, Antony, Foley, Megan, Shi, Hongliang, Swamy, Preethi, Rodstrom, Jill, Rudoltz, Marc

Volltext

CTNI-24. A PHASE 1/2 STUDY OF AVAPRITINIB IN PEDIATRIC PATIENTS WITH SOLID TUMORS DEPENDENT ON KIT OR PDGFRA SIGNALING von Chi, Susan, Hsieh, Antony, Foley, Megan, Shi, Hongliang, Swamy, Preethi, Rodstrom, Jill, Rudoltz, Marc

Volltext

Abstract CT122: Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in normal healthy volunteers von Dave, Nimita, Devlin, Marissa, Rodstrom, Jill, Yu, Bei, Foley, Megan, He, Kevin, Rasmussen, Scott, Boral, Andy, Si, Tuan Dong

Volltext

EPCT-05. A PHASE 1/2 STUDY OF AVAPRITINIB FOR KIT- OR PDGFRA-MUTANT PEDIATRIC RELAPSED/REFRACTORY SOLID TUMORS von Chi, Susan, Hsieh, Antony, Foley, Megan, Shi, Hongliang, Swamy, Preethi, Rodstrom, Jill, Rudoltz, Marc

Volltext

High Concordance Observed Between Local and Central INI1 Immunohistochemistry Results Obtained From Clinical Studies EZH-102 and EZH-202 von Hawes, Debra, Daigle, Scott, Alvarez, Rita, Corder, Ruth, Rodstrom, Jill, Blakemore, Stephen, Roche, Maria, Judkins, Alexander

Volltext

Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950) von Gounder, Mrinal M., Stacchiotti, Silvia, Schöffski, Patrick, Attia, Steven, Italiano, Antoine, Jones, Robin, Demetri, George D., Blakemore, Stephen, Clawson, Alicia, Daigle, Scott, Ribich, Scott, Roche, Maria, Rodstrom, Jill, Ho, Peter T.C., Cote, Gregory Michael

Volltext

Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950) von Schoffski, Patrick, Agulnik, Mark, Stacchiotti, Silvia, Davis, Lara Emily, Villalobos, Victor Manuel, Italiano, Antoine, George, Suzanne, Cote, Gregory Michael, Blakemore, Stephen, Clawson, Alicia, Daigle, Scott, Ribich, Scott, Roche, Maria, Rodstrom, Jill, Ho, Peter T.C., Gounder, Mrinal M.

Volltext

A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi)... von Blachly, James Stewart, Brown, Jennifer R., Barrientos, Jacqueline Claudia, Jain, Nitin, Kelly, Virginia, Garnick, Stephanie, Rodstrom, Jill, Sweeney, Jennifer, Tang, Shijie, Byrd, John C.

Volltext

Abstract A175: Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chord... von Chi, Susan, Fouladi, Maryam, Shukla, Neerav, Bourdeaut, Franck, Margol, Ashley, Makin, Guy, McCowage, Geoff, Wetmore, Cynthia, Macy, Margaret, Laetsch, Ted, Hargrave, Darren, Pinto, Navin, Yi, Joanna, Ebb, Dave, Robinson, Giles, Roche, Maria, Suttle, Benjamin, Clawson, Alicia, Ho, Peter, Rodstrom, Jill, Daigle, Scott, Nysom, Karsten

Volltext